Dr Arturo Vegas (Assistant Professor of Chemistry, Boston University Centre for Molecular Discovery, Boston, MA, US) explains the fundamentals of nanotechnology and how this can be applied to the treatment of type 1 and type 2 diabetes. He also discusses “smart” insulins, which are more glucose responsive. The use of these insulins would mean patients wouldn’t have to perform blood-sugar checks throughout the day. Dr Vegas hopes this would lead to improved long-term disease control. Finally, Dr Vegas briefly reviews the emergence of new therapies and technologies for the treatment of diabetes; he expects to see dramatic changes in the way we treat diabetes in the future.
1. What is nanotechnology? (0:13)
2. What are the latest advances in nanotechnology for the treatment of diabetes? (0:44)
3. How do you think the area of “Smart” (Gluco-Sensing) insulins will evolve over the next few years? (2:07)
4. What are your highlights from this year’s ADA meeting? (3:22)
Filmed at the American Diabetes Association (ADA) Annual Meeting, June 2018
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!